Equities analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report ($0.03) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the highest EPS estimate coming in at $0.23 and the lowest estimate coming in at ($0.23). Collegium Pharmaceutical posted earnings of ($0.10) per share during the same quarter last year, which would indicate a positive year over year growth rate of 70%. The business is scheduled to announce its next earnings report on Wednesday, February 26th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.15). For the next year, analysts expect that the firm will report earnings of $0.20 per share, with EPS estimates ranging from ($0.57) to $0.94. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The firm had revenue of $72.94 million for the quarter, compared to analysts’ expectations of $74.32 million. During the same quarter last year, the firm posted ($0.50) earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 3.9% on a year-over-year basis.
A number of research analysts recently commented on COLL shares. BidaskClub upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC decreased their price objective on Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Jefferies Financial Group upped their price target on Collegium Pharmaceutical from $26.00 to $36.00 in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. Finally, SunTrust Banks upped their price target on Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus price target of $24.57.
NASDAQ:COLL traded up $1.96 during trading hours on Friday, hitting $19.96. 1,220,900 shares of the stock were exchanged, compared to its average volume of 378,932. Collegium Pharmaceutical has a 52-week low of $10.01 and a 52-week high of $19.99. The company has a market cap of $459.95 million, a P/E ratio of -16.77 and a beta of 0.52. The firm’s fifty day moving average price is $12.16 and its 200 day moving average price is $12.08. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23.
In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 64,821 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the transaction, the chief executive officer now directly owns 242,276 shares in the company, valued at $4,547,520.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the transaction, the director now owns 64,223 shares in the company, valued at $748,197.95. The disclosure for this sale can be found here. 8.08% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Janus Henderson Group PLC raised its stake in shares of Collegium Pharmaceutical by 19.1% in the second quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after acquiring an additional 693,812 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at $3,210,000. Cortina Asset Management LLC raised its stake in shares of Collegium Pharmaceutical by 81.0% in the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after acquiring an additional 228,035 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at $2,622,000. Finally, BlackRock Inc. raised its stake in shares of Collegium Pharmaceutical by 7.1% in the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after acquiring an additional 165,018 shares in the last quarter. Institutional investors and hedge funds own 92.17% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Further Reading: Options Trading – Understanding Strike Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com